SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer

NCT07462663 on ClinicalTrials.gov · last registry update 2026-06-10

Registered but not yet open, with 80 participants planned. Due to report April 2031. Primary outcome, as filed: Recruitment Rate. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for cancer — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: NOT_YET_RECRUITING
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Hospital Universitari de Bellvitge
Sponsor type: Other
Enrollment: 80
Started: 2027-01
Primary completion: 2031-04 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Recruitment Rate

Conditions studied

Endometrial Cancer · Endometrial Cancer Stage I · Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I · Atypical Endometrial Hyperplasia · Endometrial Intraepithelial Neoplasia · Obesity & Overweight · BMI>40 · Obesity · Obesity Grade III

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.